Log In
Print
BCIQ
Print
Print this Print this
 

Aubagio, teriflunomide

Also known as: HMR1726

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionDihydroorotate dehydrogenase (DHODH) inhibitor
Molecular Target Dihydroorotate dehydrogenase (DHODH)
Mechanism of ActionDihydroorotate dehydrogenase (DHODH) inhibitor; Immune modulation
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationMultiple sclerosis (MS)
Indication DetailsPrevent or delay conversion of clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS); Treat relapsing multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

U.S. - Undisclosed Review (Treat relapsing multiple sclerosis (MS));
EU - Standard Review (Treat relapsing-remitting multiple sclerosis (RRMS));
Canada - Standard Review (Treat relapsing-remitting multiple sclerosis (RRMS))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today